Vol 15: Long-acting beta-agonists plus inhaled corticosteroids safety: a systematic review and meta-analysis of non-randomized studies.Report as inadecuate



 Vol 15: Long-acting beta-agonists plus inhaled corticosteroids safety: a systematic review and meta-analysis of non-randomized studies.


Vol 15: Long-acting beta-agonists plus inhaled corticosteroids safety: a systematic review and meta-analysis of non-randomized studies. - Download this document for free, or read online. Document in PDF available to download.

Download or read this book online for free in PDF: Vol 15: Long-acting beta-agonists plus inhaled corticosteroids safety: a systematic review and meta-analysis of non-randomized studies.
This article is from Respiratory Research, volume 15.AbstractBackground: Although several systematic reviews investigated the safety of long-acting beta‚Äďagonists LABAs in asthma, they mainly addressed randomized clinical trials while evidence from non-randomized studies has been mostly neglected. We aim to assess the risk of serious adverse events in adults and children with asthma treated with LABAs and Inhaled Corticosteroids ICs, compared to patients treated only with ICs, from published non-randomized studies. Methods: The protocol registration number was CRD42012003387 http:-www.crd.york.ac.uk-Prospero. Literature search for articles published since 1990 was performed in MEDLINE and EMBASE. Two authors selected studies independently for inclusion and extracted the data. A third reviewer resolved discrepancies. To assess the risk of serious adverse events, meta-analyses were performed calculating odds ratio summary estimators using random effect models when heterogeneity was found, and fixed effect models otherwise. Results: Of 4,415 candidate articles, 1,759 abstracts were reviewed and 220 articles were fully read. Finally, 19 studies met the inclusion criteria. Most of them were retrospective observational cohorts. Sample sizes varied from 50 to 514,216. The meta-analyses performed 69,939-624,303 participants according to the outcome considered showed that odds ratio of the LABAs and ICs combined treatment when compared with ICs alone was: 0.88 95% CI 0.69-1.12 for asthma-related hospitalization; 0.75 95% CI 0.66-0.84 for asthma-related emergency visits; 1.02 95% CI 0.94-1.10 for systemic corticosteroids; and 0.95 95% CI 0.9-1.0 for the combined outcome. Conclusions: Evidence from observational studies shows that the combined treatment of LABAs and ICs is not associated with a higher risk of serious adverse events, compared to ICs alone. Major gaps identified were prospective design, paediatric population and inclusion of mortality as a primary outcome.



Author: Hernandez, Gimena; Avila, Monica; Pont, Angels; Garin, Olatz; Alonso, Jordi; Laforest, Laurent; Cates, Christopher J; Ferrer, Montserrat

Source: https://archive.org/







Related documents